EPO and chronic kidney disease: Assuming that when epoetin SEBs are introduced into the Canadian market, they will be at 78% of the originator’s price (as the average in EU), that the originator’s price will be reduced by 13% and taking into account the cost of treatment for different stages of CKD, including the number of patients receiving treatment with ESAs or SEBs, the expected annual cost of treatment for years 1 to 5 are as shown in Tables 4, 5, 6, 7 and 8.